Paper32395366
NK Cell-Based Immunotherapies in Cancer.
Shin MH and 5 others. Immune Netw, 2020. Cited by 113 papers, by iCite.
Cite this record
ConductScience Library. NK Cell-Based Immunotherapies in Cancer. Papers, record 32395366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32395366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References128
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 2 | 15928678 | MHC class Ib molecules bridge innate and acquired immunity. | Nat Rev Immunol | 2005 | https://conductscience.org/library/papers/15928678 | PubMed |
| 3 | 25096406 | Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. | Genome Res | 2014 | https://conductscience.org/library/papers/25096406 | PubMed |
| 4 | 10365666 | Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. | Hum Gene Ther | 1999 | https://conductscience.org/library/papers/10365666 | PubMed |
| 5 | 21698239 | Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. | PLoS One | 2011 | https://conductscience.org/library/papers/21698239 | PubMed |
| 6 | 25001465 | Therapeutic vaccines for cancer: an overview of clinical trials. | Nat Rev Clin Oncol | 2014 | https://conductscience.org/library/papers/25001465 | PubMed |
| 7 | 31244577 | CAR-Expressing Natural Killer Cells for Cancer Retargeting. | Transfus Med Hemother | 2019 | https://conductscience.org/library/papers/31244577 | PubMed |
| 8 | 24099156 | Transcriptional regulation by hypoxia inducible factors. | Crit Rev Biochem Mol Biol | 2014 | https://conductscience.org/library/papers/24099156 | PubMed |
| 9 | 2793204 | Kinetics of cellular cytotoxicity mediated by a cloned human natural killer cell line. | Immunobiology | 1989 | https://conductscience.org/library/papers/2793204 | PubMed |
| 10 | 15016654 | Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. | Blood | 2004 | https://conductscience.org/library/papers/15016654 | PubMed |
| 11 | 19278418 | Natural killer cells: integrating diversity with function. | Immunology | 2009 | https://conductscience.org/library/papers/19278418 | PubMed |
| 12 | 25355530 | SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. | Nat Commun | 2014 | https://conductscience.org/library/papers/25355530 | PubMed |
| 13 | 22658128 | Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658128 | PubMed |
| 14 | 28887358 | First-Ever CAR T-cell Therapy Approved in U.S. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28887358 | PubMed |
| 15 | 24094496 | Treatment of patients with advanced cancer with the natural killer cell line NK-92. | Cytotherapy | 2013 | https://conductscience.org/library/papers/24094496 | PubMed |
| 16 | 9486650 | HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. | Nature | 1998 | https://conductscience.org/library/papers/9486650 | PubMed |
| 17 | 23515118 | Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. | Stem Cells Transl Med | 2013 | https://conductscience.org/library/papers/23515118 | PubMed |
| 18 | 23596445 | The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection. | Front Immunol | 2013 | https://conductscience.org/library/papers/23596445 | PubMed |
| 19 | 20525992 | Improved survival with ipilimumab in patients with metastatic melanoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20525992 | PubMed |
| 20 | 22279576 | Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. | PLoS One | 2012 | https://conductscience.org/library/papers/22279576 | PubMed |
Cited by88
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 113 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42799209 | Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42799209 | PubMed |
| 42316257 | Cellular immunotherapy in melanoma: the next frontier in cancer treatment. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42316257 | PubMed |
| 42243832 | Exploring CAR cell therapies beyond CAR-T for myeloid malignancies. | J Biomed Sci | 2026 | https://conductscience.org/library/papers/42243832 | PubMed |
| 41930159 | Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer. | Oncol Res | 2026 | https://conductscience.org/library/papers/41930159 | PubMed |
| 41828675 | Heat up and Destroy: Immunotherapy of "Cold" Tumors Using the Example of Glioblastoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828675 | PubMed |
| 41799416 | Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy. | Pharm Sci Adv | 2026 | https://conductscience.org/library/papers/41799416 | PubMed |
| 41580832 | NK cell infusion is well-tolerated and shows preliminary efficacy in patients with recurrent hepatocellular carcinoma post-liver transplantation : a phase I trial. | J Transl Med | 2026 | https://conductscience.org/library/papers/41580832 | PubMed |
| 40872545 | Unconventional Immunotherapies in Cancer: Opportunities and Challenges. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40872545 | PubMed |
| 40650799 | Stem Cell for Cancer Immunotherapy: Current Approaches and Challenges. | Stem Cell Rev Rep | 2025 | https://conductscience.org/library/papers/40650799 | PubMed |
| 40597275 | Robo1 CAR-NK92 and radiotherapy exert synergistic efficacy in solid tumors. | J Transl Med | 2025 | https://conductscience.org/library/papers/40597275 | PubMed |
| 40563618 | The Natural Killer Cell Line NK-92 and Its Genetic Variants: Impact on NK Cell Research and Cancer Immunotherapy. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40563618 | PubMed |
| 40551137 | Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma. | Mol Med | 2025 | https://conductscience.org/library/papers/40551137 | PubMed |
| 40510336 | Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells. | Front Immunol | 2025 | https://conductscience.org/library/papers/40510336 | PubMed |
| 40342534 | Natural killer cells in combination with the inhibition of telomerase induced apoptosis in Acute Myeloid Leukemia cells. | Biochem Biophys Rep | 2025 | https://conductscience.org/library/papers/40342534 | PubMed |
| 40299429 | The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances. | Biomedicines | 2025 | https://conductscience.org/library/papers/40299429 | PubMed |
| 40230883 | Nanoimmunotherapy: the smart trooper for cancer therapy. | Explor Target Antitumor Ther | 2025 | https://conductscience.org/library/papers/40230883 | PubMed |
| 40227707 | Gene and Cell Therapy for Sarcomas: A Review. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40227707 | PubMed |
| 40076856 | Enhanced Anti-Tumor Effects of Natural Killer Cell-Derived Exosomes Through Doxorubicin Delivery to Hepatocellular Carcinoma Cells: Cytotoxicity and Apoptosis Study. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40076856 | PubMed |
| 39920524 | Integration of single-cell and bulk RNA-sequencing data to construct and validate a signature based on NK cell marker genes to predict immunotherapy response and prognosis in colorectal cancer. | Discov Oncol | 2025 | https://conductscience.org/library/papers/39920524 | PubMed |
| 39852540 | Polysaccharide Fraction Isolated from Saccharina japonica Exhibits Anti-Cancer Effects Through Immunostimulating Activities. | Mar Drugs | 2025 | https://conductscience.org/library/papers/39852540 | PubMed |
Genes85
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32395366
GET https://conductscience.org/api/papers/v1/32395366/references?page=2